SomaLogic expects to exceed previous sales projections by at least 10%

BOULDER — SomaLogic Inc., a Boulder-based biotechnology firm on the verge of going public with a merger with special purpose acquisition company CM Life Sciences II (Nasdaq: CMIIU), expects its post-merger revenue figures to be significantly higher than previously anticipated. 

The company, which develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning, disclosed Monday that it thinks it will beat its previous full-year 2021 revenue guidance of $66.7 million by 10% or more. Gross margins are expected to be more…